Curaleaf Holding’s months-long hostile takeover bid for Aurora Hashish has been blown out of the water by Organigram International, which has now tabled a considerably increased bid.
Yesterday (November 03), Canada’s Organigram tabled a suggestion for Aurora of C$7.80 per share, equating to roughly C$561m.
It marks the primary time that Organigram has publicly acknowledged an curiosity in Aurora since reviews emerged final month that the pair had been in parallel talks, and Aurora’s board has unanimously beneficial that shareholders settle for its bid.
Their suggestion will come as little shock to shareholders, who’ve been buffeted by repeated and more and more acrimonious statements from each Aurora’s and Curaleaf’s administration groups for the reason that latter first introduced plans to launch a hostile takeover in August.
Curaleaf has already raised its preliminary bid by 25% to US$5 per share and has assured stakeholders that this supply will stay open till December 04. Nevertheless, with Organigram’s supply representing a 21% premium on Curaleaf’s bid worth, backed by a £100m (C$187.5m) contribution from tobacco large British American Tobacco (BAT), Curaleaf’s probability of successful over shareholders appears more and more unlikely.
Inside Organigram’s supply
A joint assertion from Aurora and Organigram frames the transaction as a certainty, an ‘association settlement’ now signed by the pair, regardless of being strongly beneficial by Aurora, is little greater than a proposal till its shareholders vote it by.
In line with the assertion, ‘particulars of the transaction’ and required shareholder votes might be despatched to the businesses’ respective shareholders in ‘due course’. Neither firm has scheduled a selected date for the voting to happen but, however each are anticipated in December 2026.
Past shareholder approvals, the transaction will ‘be topic to regulatory approvals, in addition to the approval of the Supreme Court docket of British Columbia’, and international direct funding clearance from Germany’s Federal Ministry for Financial Affairs and Power. The pair anticipated it to be ‘accomplished in January 2027’.
Underneath the phrases of the association settlement, Aurora shareholders can select how they take the C$7.80 per share consideration. They will elect to obtain the complete quantity in money, 5.8626 Organigram frequent shares, or a mixed package deal of C$3.75 money plus 3.0431 Organigram shares.
The money portion of the deal, price as much as C$253.6m, is funded by Organigram’s present money available, the C$187.5m BAT non-public placement, and a brand new C$210m senior secured credit score facility from ATB Monetary.
Huge tobacco’s large transfer
BAT, which at present owns a 30% stake in Organigram, has dedicated to subscribing for 141.0m Organigram frequent shares at C$1.33 every, for gross proceeds of C$187.5m, earmarked particularly to fund the money element of the deal.
Ought to the deal full, BAT would personal a 42% stake within the newly mixed entity, however its voting rights will stay capped at 30%.
As such, the tobacco large would personal almost half of what’s set to be one of many world’s largest hashish corporations.
The mixed enterprise would grow to be the biggest publicly traded Canadian hashish firm by income and the clearest chief within the nationally regulated markets exterior the US, although mixed last-twelve-month income of C$623m sits properly under Curaleaf’s roughly US$1.4bn, the present world income chief.
BAT has additionally signed an irrevocable voting settlement committing it to vote in favour of the transaction and in opposition to any competing proposal. The settlement isn’t terminable till six months after any termination of the association settlement itself, a lock-in designed to discourage a counter-bid.
On a professional forma foundation, Aurora shareholders will emerge with roughly 35% financial possession and 42% voting possession of the mixed firm on a totally diluted foundation.
Different Organigram shareholders maintain 24% financial and 28% voting. In line with Organigram’s November 03 transaction presentation, the mixed enterprise will carry last-twelve-month income of C$623m, gross revenue of C$254m and adjusted EBITDA of C$80m.
The businesses anticipate to save lots of greater than C$50m a yr by bulk buying, merged distribution, decrease head-office prices and shifting manufacturing to the most cost effective certified facility.
The European footprint
As we mentioned when first reporting Curaleaf’s curiosity in Aurora, the actual prize is management of its European footprint.
With Organigram and Aurora combining their operations, the brand new entity would function 5 EU-GMP licensed manufacturing and distribution amenities throughout Canada and Germany, carrying roughly 75 metric tonnes of EU-GMP licensed manufacturing capability and round 170 metric tonnes of complete flower capability throughout 14 websites.
Aurora’s Leuna facility in Saxony-Anhalt, lately renamed Aurora Horizon after a capability enlargement, sits alongside Organigram’s lately built-in Sanity Group, which brings a multi-brand German medical and shopper platform together with Vayamed, VAAY and Grashaus Initiatives.
The mixed enterprise would declare management positions in Germany, Canada, Poland, Australia and New Zealand, with additional presence or deliberate enlargement into the UK, France, Ukraine, Czechia, Sweden, Switzerland, Malta, Barbados and the Cayman Islands. Organigram’s transaction presentation describes the mixed EU-GMP footprint as ‘costly and time-consuming for rivals to duplicate’.
Organigram’s CEO James Yamanaka stated the deal would convey collectively ‘Aurora’s established world medical hashish platform with our Canadian operations and rising worldwide footprint’ to create ‘a bigger, stronger, and extra diversified firm’.
Miguel Martin, Govt Chairman and Chief Govt Officer of Aurora, stated the mixture would speed up Aurora’s ‘worldwide development technique by strengthening business execution, increasing our product and R&D capabilities, and increasing our world working community’.
Prohibition Companions valued the German medical hashish market at €1.15bn in 2025 and expects European medical hashish gross sales to greater than double by 2028 in the European Hashish Report.
